Abstract 181P
Background
Based on the phase III REFLECT study, lenvatinib (LEN) has been recommended as a first-line (1L) therapy for uHCC since 2018. Recent years have seen a further expansion of 1L treatment recommendations for uHCC, to include atezolizumab+bevacizumab, nivolumab, FOLFOX4 and donafenib. We conducted a network meta-analysis (NMA) to compare the efficacy and safety of lenvatinib with other systemic therapies in first-line uHCC.
Methods
A systematic literature review identified randomized, controlled, multicenter trials in adults with advanced HCC who had received no prior systemic therapy. Literature retrieval was conducted using PubMed, ScienceDirect, the Cochrane Database, EMBASE and other sources. Objective response rate (ORR), disease progression-free survival (PFS), time-to-progression (TTP) and treatment discontinuations due to adverse events (AEs) were extracted from published studies and quantitatively pooled using frequentist NMA. Pairwise risk ratio(RR), hazard ratio(HR) with confidence interval was calculated. The P-scores were used to rank each treatment.
Results
In total, 1398 records were screened and 27 were eligible for analysis, and the treatments included were atezolizumab+bevacizumab, brivanib, FOLFOX4, donafenib, dovitinib, lenvatinib, linifanib, nintedanib, nivolumab, sorafenib, sunitinib, vandetanib, 11 sorafenib combination therapies and three other combination therapies. For ORR and TTP, lenvatinib was ranked first (P-scores: 0.88 and 0.99), for PFS, atezolizumab+bevacizumab was ranked first followed by lenvatinib (HR: 0.89; 95% CI, 0.64-1.25; P-scores: 0.95 and 0.90) and donafinib and nivolumab ranked 5th and 6th (HR: 1.38; 95% CI, 1.09-1.73, HR: 1.41; 95% CI, 1.13-1.76; P scores: 0.90 vs 0.59 vs 0.56 respectively). Atezolizumab+bevacizumab was associated with the highest probability of discontinuation due to AEs (RR: 1.27 [0.35-4.60]), lenvatinib ranked 4th (P scores: 0.25 and 0.39, respectively).
Conclusions
This NMA suggested that greater ORR and TTP benefits with first-line use of Lenvatinib than others. Although Atezolizumab+Bevacizumab showed more benefit in PFS, more discontinuation because of AE should also take into consideration.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
34P - Clinical significance of neoadjuvant dose-dense chemotherapy for II and III stage breast cancer: A meta-analysis of published studies
Presenter: Meng chen Liu
Session: e-Poster Display Session
35P - Pathological response to weekly nabpaclitaxel and carboplatin followed by anthracycline regimen in triple negative breast cancer
Presenter: Goteti Sharat Chandra
Session: e-Poster Display Session
36P - Survival in patients with contralateral breast cancer
Presenter: Sergey Kamishov
Session: e-Poster Display Session
37P - Correlation between haematological toxicity with quality of life in breast cancer patients after first-cycle chemotherapy
Presenter: felix Wijovi
Session: e-Poster Display Session
38P - Evaluation of the prognostic value of innate immunity-related biomarkers in early breast cancer (BC)
Presenter: Veronica Martini
Session: e-Poster Display Session
39P - CSF-1R inhibitor (C019199) enhances antitumor effect in combination with anti-PD-1 therapy on murine breast cancer models
Presenter: Jiani Zheng
Session: e-Poster Display Session
40P - Molecular subtypes and imaging phenotypes of breast cancer: MRI
Presenter: Yulduz Khatamovna
Session: e-Poster Display Session
41P - Mir-223 overexpression is associated with increased expression of EGFR and worse prognosis in Indonesian TNBC patients
Presenter: Ibnu Purwanto
Session: e-Poster Display Session
42P - Impact of germline mutations on breast cancer prognosis in Kazakh population
Presenter: Dilyara Kaidarova
Session: e-Poster Display Session
50P - Efficacy and safety analysis of pyrotinib in lapatinib resistant HER2-positive metastatic breast cancer: A retrospective study
Presenter: Yijia Hua
Session: e-Poster Display Session